Roche (RHHBY) announced that the European Commission has approved Itovebi, in combination with palbociclib and fulvestrant, for the treatment of adult patients with PIK3CA-mutated, oestrogen receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment. These results were reinforced by the INAVO120 final overall survival analysis that showed the Itovebi-based regimen reduced the risk of death by 33%. Additionally, the treatment regimen substantially delayed the time to chemotherapy by approximately two years compared with palbociclib and fulvestrant alone.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- AstraZeneca (AZN) Commits to $50B U.S. Investment as Tariff Threat Looms
- Roche announces ALIENTO trial meets, ARNASA study misses primary endpoint
- Genetech: STARGLO data does not provide sufficient evidence for DLBCL indication
- Trump says drug tariffs probable by August 1, semis coming soon, Bloomberg says
- FDA willing to trade faster drug reviews for lower prices, Bloomberg reports